I'll start with the question of the long-term biomanufacturing capacity in Canada. It's a matter of great importance, and in fact, the government recognized in the fall economic statement that a full plan and full engagement with Canadians, which is now under way under the leadership of Innovation, Science and Economic Development to build that capability out in terms of productive capacities, was necessary. In fact, it's necessary because we have all of the intellectual leadership, the scientific leadership and the capability in terms of research and breakthroughs, which is demonstrated by the candidates that we're supporting through NRC IRAP and other vaccine projects that are under way in Canada, that we can deliver the end-to-end solution to Canadians.
Certainly it's something that this COVID-19 pandemic has illustrated for us, the need to catch up and make significant investments, which, of course, the government has indicated it's prepared to follow through on and is doing. For example, the biologics manufacturing centre the NRC is currently constructing will be a long-term facility that will be available for pandemic use and be a reserve capacity for the country.
I would say that, concerning the vaccine candidates that we're working with through the NRC IRAP, we're in close contact with each of them, following their clinical progress and following their pursuit of their study, and again, we'll be prepared to follow up and work with them on an ongoing basis to support their needs going forward as they have success in their development programs. Obviously, this will establish a strong group of made-in-Canada candidates with Canadian IP with the ability to pursue those projects for Canadians.